Lake Street Reiterates Buy Rating on InspireMD with $5 Price Target

Lake Street maintains a Buy rating for InspireMD with a $5.00 price target. The company's shares closed at $2.26. Analyst Frank Takkinen has a 37.54% success rate on recommended stocks and a Moderate Buy consensus with a $4.50 price target. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84.

InspireMD Inc (NASDAQ:NSPR) has seen its stock price fluctuate, with shares closing at $2.26 on July 2, 2025. The company, which focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases, has received various analyst ratings and price targets.

Lake Street maintains a Buy rating for InspireMD with a $5.00 price target [1]. Analyst Frank Takkinen, who has a 37.54% success rate on recommended stocks, has a Moderate Buy consensus with a $4.50 price target [2]. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84, indicating a significant undervaluation compared to its peers.

InspireMD's recent news includes the commercial launch of its CGuard Prime carotid stent system in the United States, following FDA approval [3]. The company also announced the appointment of Michael Lawless as its new CFO [4]. These developments have driven a 4% increase in pre-market trading, suggesting investor optimism.

Despite the recent positive news, InspireMD's stock price has been volatile, with a 52-week range of $1.99 to $3.798. The company's net income was -$36.139, and its EPS was -$0.79, indicating financial challenges. However, the company holds more cash than debt on its balance sheet, providing some financial stability.

In conclusion, InspireMD Inc's stock presents both risks and opportunities for investors. With analyst ratings suggesting a potential upside, investors should carefully consider the company's financial health and recent developments before making investment decisions.

References:
[1] https://www.investing.com/equities/inspiremd-inc
[2] https://www.investing.com/equities/inspiremd-inc
[3] https://www.investing.com/news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-2635453
[4] https://www.investing.com/news/inspiremd-names-michael-lawless-as-new-cfo-2635454